Contact: Brooks M. Hybertson, PhD  
Location: Longmont, CO  
Email: bhybertson@aerophase.com  
Tel: 303.651.2633  
Website: www.aerophase.com

Company Overview

Industry Sector: Pharmaceuticals

Company Overview: Aerophase, Inc. is a specialty pharmaceutical company that is leading the effort to treat lung cancer with drugs delivered as aerosols directly into the lungs. Aerophase’s lead product is Pulmitaxel™, an aerosol formulation of paclitaxel for the treatment of nonsmall cell lung cancer with demonstrated preclinical efficacy. This devastating illness claims the lives of approximately 150,000 patients in the US each year, and better therapies are greatly needed.

Target Market(s): Pulmonary Oncology patients in hospitals and clinics.

Key Value Drivers

Technology*: Pulmitaxel™ is a proprietary aerosol formulation of paclitaxel intended to treat nonsmall cell lung cancer using Aerophase’s patented technology which facilitates the inhalation aerosol delivery of lipophilic anticancer agents into the lungs.

Competitive Advantage: Currently, the primary options available to treat lung cancer are surgery, radiation, and systemic chemotherapy. Aerosol drug delivery to the lungs may be a new, better option. The advantage of Pulmitaxel™ is that it delivers therapeutic levels of paclitaxel directly to the lung tumor site by inhalation, thus reducing the consequence of treating the whole body with mitotic inhibitors, using smaller amounts of costly drugs, and possibly improving therapeutic outcomes.

Plan & Strategy: Aerophase is seeking strategic partnerships with big pharmaceutical companies and with equity investors to facilitate IND filing and initiation of phase 1 human clinical trials.

*Technology funded by the NCI and being commercialized under the NIH-CAP

Management

Leadership:
Brian N. Hansen, PhD, President and CEO
Brooks M. Hybertson, MBA, PhD, VP of R&D
John F. Fletcher, Head Engineer
Connor J. McCue, VP of Business Development

Scientific Advisors:
Douglas H. Thamm, VMD: Associate Professor, Colorado State University
Daniel L. Gustafson, PhD: Associate Professor, Colorado State University

Product Pipeline

<table>
<thead>
<tr>
<th>Product</th>
<th>R&amp;D</th>
<th>Preclinical animal studies</th>
<th>IND</th>
<th>Phase 1 clinical trial</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pulmitaxel™</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AERP-2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AERP-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>